Core Insights - NeOnc Technologies Holdings, Inc. has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment, aimed at advancing treatments for brain and central nervous system cancers [2][3][4] Company Overview - NeOnc is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system cancers, utilizing its proprietary NEO™ drug development platform [6] - The company has a portfolio of novel drug candidates, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and Investigational New Drug status [6] Strategic Partnership Details - The agreement includes Quazar acquiring 1.4 million shares of NeOnc at $25 per share, totaling $35 million, with an additional $15 million allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA region [4] - Quazar plans to lead a capital formation round of up to $50 million, with 70% of proceeds directed towards acquiring NeOnc common stock and 30% for clinical trials and infrastructure [4] Future Plans and Conditions - NeOnc must fulfill certain conditions within 120 days, including the legal formation of NuroMENA and NuroCure in Abu Dhabi, for the transaction to be completed [5]

Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [2] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates and delivery methods, with patent protections extending to 2038 [2] - NeOnc's proprietary chemotherapy agents have shown positive effects in laboratory tests and clinical trials, particularly for malignant gliomas [2] Current Developments - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [2] - The company has an exclusive worldwide patent portfolio licensed from the University of Southern California, covering multiple uses for NEO100, NEO212, and other products [2] Upcoming Events - Management will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, providing an opportunity for investors to schedule one-on-one meetings [1]

Core Points - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [1][4] - The company will have its Executive Chairman, Amir Heshmatpour, featured in a live interview on July 24, 2025, at 11:00 a.m. ET [1] - NeOnc has executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment [2] - The company has been included in the Russell Microcap Index, which is part of its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is dedicated to developing and commercializing therapeutics that address challenges in overcoming the blood-brain barrier [4] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [4] - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [4]

Core Insights - NeOnc Technologies Holdings, Inc. is advancing transformative treatments for brain and central nervous system cancers and is featured in a live interview with financial commentator Kenny Polcari [1][4] - The company executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment, aimed at expanding its market presence in the UAE and broader GCC and MENA regions [2] - NeOnc was included in the Russell Microcap Index, which aligns with its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is a clinical-stage life sciences company focused on developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [4] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and IND status [4]

Core Insights - NeOnc Technologies Holdings, Inc. has achieved a significant milestone by executing a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, covering the UAE and wider GCC and MENA region for its therapeutics NEO100 and NEO212 [1][2] - The company is progressing towards a strategic partnership with Quazar Investment, which includes a potential $50 million equity investment aimed at expanding operations in the MENA region [2][5] - NeOnc's inclusion in the Russell Microcap Index is strategically timed with the Quazar partnership to attract institutional capital and enhance market liquidity [3] Company Developments - The Sub-License Agreement is the second of five required conditions for closing the transaction with Quazar, indicating progress in the partnership [2][5] - The proposed capital formation round led by Quazar is priced at $25 per share, with 70% of proceeds allocated for acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the MENA region [5] - NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, showcasing the company's commitment to advancing life-saving therapies [6] Strategic Goals - The completion of the Sub-License Agreement is viewed as a critical step in unlocking the full potential of the $50 million partnership, aimed at delivering long-term value to shareholders [4] - The company is undergoing a transformation from a clinical-stage biotech to a global brain cancer platform, as noted by industry experts [4] - NeOnc has an extensive patent portfolio licensed from the University of Southern California, which supports its drug development efforts and extends patent protections to 2038 [6]

Core Insights - NeOnc Technologies Holdings, Inc. has received formal approval from its Board of Directors for a strategic transaction with Quazar Investment, marking a significant step towards closing the deal [1][2][3] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, utilizing its NEO™ drug development platform [5] - The company’s proprietary chemotherapy agents, including NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [5] Strategic Partnership - The Board's unanimous approval allows NeOnc to participate in a $50 million equity investment and expansion into the MENA region under a non-binding term sheet with Quazar [2][3] - Quazar plans to lead a capital formation round priced at $25 per share, with 70% of proceeds allocated to acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the UAE and MENA region [3] Transaction Milestones - The transaction requires NeOnc to meet five milestones, with the current Board approval being the first of these [2][4] - NeOnc has 120 days to satisfy the remaining conditions necessary for closing the transaction [4] Future Developments - The strategic partnership aims to establish a strong operational presence in the MENA region and accelerate the clinical development of NeOnc's core assets [3] - Key future actions include the legal formation of NuroMENA and NuroCure in Abu Dhabi, execution of a Sub-License Agreement, finalization of offering documents, and approval of a comprehensive business plan [8]

Core Insights - NeOnc Technologies Holdings, Inc. has been included in the Russell Microcap® Index, which is a significant recognition of the company's growth and commitment to shareholder value [1][3] - The Russell Microcap® Index includes companies with an average market capitalization of approximately $640 million, covering stocks ranging from about $30 million to $3 billion [3][4] - NeOnc is focused on advancing its Phase II clinical trials for CNS cancers and expanding into the MENA region through a proposed partnership with Quazar [3] Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system cancers and disorders [1][6] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates with patent protections extending to 2038 [6] - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] Industry Context - The Russell US Indexes reconstitution ranks the 4,000 largest US stocks by total market capitalization, and membership in the Russell Microcap® Index is valid for one year [2][4] - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [4]

Core Insights - NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to establish a new investment and clinical platform in the MENA region [1][2] - The partnership aims to leverage the UAE's clinical trial infrastructure to advance NeOnc's late-stage drug candidates [3][7] Investment and Structure - The term sheet outlines the formation of NuroMENA Holdings Ltd, which will oversee the establishment of NuroCure, an Abu Dhabi-based subsidiary responsible for clinical trials [2][5] - A proposed equity investment of $50 million is contingent upon NeOnc meeting specific conditions within 120 days [4][8] Clinical Development - NuroCure will initiate clinical trials for NEO100 and NEO212, targeting aggressive brain cancers such as Diffuse Intrinsic Pontine Glioma and glioblastoma multiforme [7][9] - The partnership is positioned to enhance NeOnc's clinical programs through collaboration with Cleveland Clinic Abu Dhabi [3][10] Financial Strategy - Quazar will lead a capital formation round of up to $50 million, with 70% allocated for acquiring NeOnc common stock and 30% for clinical trial and infrastructure development [8][10] - The investment strategy includes executing a Sub-License Agreement for NEO100 and NEO212, facilitating clinical efforts in the region [5][11] Company Background - NeOnc Technologies is focused on developing therapeutics for central nervous system cancers, with a robust patent portfolio extending to 2038 [11] - The company's drug candidates, NEO100 and NEO212, are currently in Phase II clinical trials under FDA Fast-Track status [11]

As filed with the Securities and Exchange Commission on June 6, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeOnc Technologies Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 92-1954864 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 23975 Park ...

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as Chief Clinical Officer to enhance its clinical development strategy and accelerate clinical trials, particularly for its lead asset NEO100, which is nearing completion of Phase 2a ahead of schedule [1][5]. Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on innovative therapies for central nervous system cancers, with lead programs including NEO100 and NEO212 designed to bypass the blood-brain barrier [6]. Leadership Appointment - Dr. Neman joins from the Keck School of Medicine at USC, where he has significant experience in cancer neuroscience and has led various cancer research initiatives [2][3]. - His expertise in brain tumor biology and clinical leadership is expected to be instrumental in advancing NeOnc's mission to improve treatment outcomes for patients with life-threatening cancers [5]. Clinical Trials and Development - NeOnc is currently conducting four clinical trials, with NEO100's Phase 2a trial achieving full enrollment ahead of schedule [5]. - The company aims to integrate AI and quantum computing into its drug delivery platform, enhancing its precision therapies [5]. Research and Innovation - NeOnc's proprietary formulations and extensive patent portfolio (176 patents worldwide) reflect its strong potential for commercialization in the CNS cancer treatment market [6].